In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli | Zendy

J. H. Jorgensen | Zendy; Sharon A. Crawford | Zendy; G A Alexander | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli

Author(s) -

J. H. Jorgensen,

Sharon A. Crawford,

G A Alexander

Publication year - 1980

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.17.6.937

Subject(s) - moxalactam , cefoxitin , cefotaxime , microbiology and biotechnology , carbenicillin , providencia , proteus vulgaris , enterobacter , cephalosporin , cefamandole , amikacin , proteus , serratia , citrobacter , klebsiella , biology , antibiotics , pseudomonas , gentamicin , pseudomonas aeruginosa , bacteria , escherichia coli , biochemistry , staphylococcus aureus , genetics , gene

The in vitro activities of two new beta-lactam antibiotics, moxalactam disodium (LY 127935) and cefotaxime (HR-756), were compared with cefoxitin, cefamandole, cefuroxime, cephalothin, and, in some instances, carbenicillin, gentamicin, and amikacin against aerobic gram-negative bacilli. Test isolates included normally cephalosporin-resistant members of the Enterobacteriaceae and Pseudomonas spp. and a variety of nonfermentative or oxidase-positive bacteria. Both moxalactam and cefotaxime demonstrated impressive in vitro activities against both groups of microorganisms. The two new drugs were clearly more active than any of the other beta-lactam antibiotics against species of Escherichia, Citrobacter, Enterobacter, Klebsiella, Proteus, Providencia, Pseudomonas, and Serratia. An additive or synergistic effect could also be demonstrated with the majority of Pseudomonas and Serratia isolates when either moxalactam or defotaxime was combined with amikacin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research